Q2 2023 13F Holders as of 30 Jun 2023
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
383M
-
Number of holders
-
300
-
Total 13F shares, excl. options
-
1.14B
-
Shares change
-
+71.6M
-
Total reported value, excl. options
-
$2.12B
-
Value change
-
+$141M
-
Put/Call ratio
-
2
-
Number of buys
-
155
-
Number of sells
-
-99
-
Price
-
$1.86
Significant Holders of RECURSION PHARMACEUTICALS, INC. - Common Stock (DNA) as of Q2 2023
359 filings reported holding DNA - RECURSION PHARMACEUTICALS, INC. - Common Stock as of Q2 2023.
RECURSION PHARMACEUTICALS, INC. - Common Stock (DNA) has 300 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 1.14B shares
.
Largest 10 shareholders include BAILLIE GIFFORD & CO (241M shares), ARK Investment Management LLC (170M shares), VIKING GLOBAL INVESTORS LP (143M shares), VANGUARD GROUP INC (128M shares), Anchorage Capital Group, L.L.C. (69.9M shares), BlackRock Inc. (68.2M shares), Sumitomo Mitsui Trust Holdings, Inc. (50.8M shares), Nikko Asset Management Americas, Inc. (50.8M shares), GENERAL ATLANTIC, L.P. (32.3M shares), and SB INVESTMENT ADVISERS (UK) LTD (24.4M shares).
This table shows the top 300 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.